Impact on abiraterone pharmacokinetics (PK) and safety: Open-label drug-drug interaction (DDI) studies with ketoconazole and rifampicin

被引：0
|
作者：
Chien, C. [1 ]
Bernard, A. [2 ]
Vaccaro, N. [3 ]
Acharya, M. [2 ]
Jiao, J. [4 ]
Monbaliu, J. [5 ]
De Vries, R. [6 ]
Stieltjes, H. [6 ]
Yu, M. K. [7 ]
Tran, N. P. [7 ]
机构：
[1] Janssen Res & Dev, Clin Pharmacol, Titusville, NJ USA
[2] Janssen Res & Dev, Clin Pharmacol, Raritan, NJ USA
[3] Janssen Res & Dev, Clin Pharmacol, San Diego, CA USA
[4] Janssen Res & Dev, Biometr & Reporting, Raritan, NJ USA
[5] Janssen Res & Dev, Preclin Project Dev, Beerse, Belgium
[6] Janssen Res & Dev, Bioanal, Beerse, Belgium
[7] Janssen Res & Dev, WC Clin Oncol, Los Angeles, CA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2917
引用
收藏
页码：S702 / S703
页数：2
相关论文
共 50 条
  • [1] Impact on Abiraterone Pharmacokinetics and Safety: Open-Label Drug-Drug Interaction Studies with Ketoconazole and Rifampicin
    Bernard, Apexa
    Vaccaro, Nicole
    Acharya, Milin
    Jiao, James
    Monbaliu, Johan
    De Vries, Ronald
    Stieltjes, Hans
    Yu, Margaret
    Tran, Namphuong
    Chien, Caly
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2015, 4 (01): : 63 - 73
  • [2] Pharmacokinetics and Safety of Coadministered Atogepant and Topiramate in Healthy Participants: A Phase 1, Open-Label, Drug-Drug Interaction Study
    Boinpally, Ramesh
    McGeeney, Danielle
    Borbridge, Lisa
    Trugman, Joel
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2023, 12 (10): : 1013 - 1021
  • [3] Lack of Drug-Drug Interaction (DDI) between Necitumumab and Gemcitabine or Cisplatin: A Phase 2, Open-Label, Nonrandomized Study
    Chaudhary, Archana
    Chao, Grace
    Braiteh, Fadi
    Gordon, Michael
    Lee, James
    Lorusso, Patricia
    Obasaju, Coleman
    Wallin, Johan
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S928 - S929
  • [4] A drug-drug interaction (DDI) study to assess the effect of oral galeterone on the pharmacokinetics (PK) of oral midazolam
    Ferrante, Karen J.
    Jacoby, Douglas B.
    Sonnichsen, Daryl
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [5] A survey of drug-drug interaction (DDI) studies.
    Marroum, P
    Burnett, A
    Svadjian, R
    Uppoor, RS
    Ajayi, F
    Yuan, R
    Lesko, LJ
    Balian, JD
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 147 - 147
  • [6] AN OPEN-LABEL, PHASE 1 STUDY TO EVALUATE THE PHARMACOKINETICS (PK) AND DRUG-DRUG INTERACTIONS OF SETANAXIB TABLETS IN HEALTHY ADULTS
    Szyndralewiez, Cedric
    Laurijssens, Bart
    Carlsson, Stefan
    Philipson, Richard
    [J]. HEPATOLOGY, 2022, 76 : S1468 - S1468
  • [7] Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study
    Poggesi, Italo
    Li, Lilian Y.
    Jiao, James
    Hellemans, Peter
    Rasschaert, Freya
    de Zwart, Loeckie
    Snoeys, Jan
    De Meulder, Marc
    Mamidi, Rao N. V. S.
    Ouellet, Daniele
    [J]. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2020, 45 (01) : 101 - 111
  • [8] Effects of Acetaminophen, Naproxen, and Acetylsalicylic Acid on Tapentadol Pharmacokinetics: Results of Two Randomized, Open-Label, Crossover, Drug-Drug Interaction Studies
    Smit, Johan W.
    Oh, Charles
    Rengelshausen, Jens
    Terlinden, Rolf
    Ravenstijn, Paulien G. M.
    Wang, Shean-Sheng
    Upmalis, David
    Mangold, Bernhard
    [J]. PHARMACOTHERAPY, 2010, 30 (01): : 25 - 34
  • [9] Pharmacokinetics and Safety of Atogepant Co-administered with Quinidine Gluconate in Healthy Participants: A Phase 1, Open-Label, Drug-Drug Interaction Study
    Boinpally, Ramesh
    Borbridge, Lisa
    Wangsadipura, Veronica
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (08): : 930 - 937
  • [10] PHARMACOKINETIC (PK) BASIS OF STATIN DRUG-DRUG INTERACTION (DDI) INFORMATION IN FDA LABELS
    Mease, J.
    Ramamoorthy, A.
    Yang, X.
    Madabushi, R.
    Fletcher, E. Pfuma
    Zineh, I.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S13 - S13
12345